MX2013004981A - Composiciones y metodos para la administracion de agentes terapeuticos. - Google Patents

Composiciones y metodos para la administracion de agentes terapeuticos.

Info

Publication number
MX2013004981A
MX2013004981A MX2013004981A MX2013004981A MX2013004981A MX 2013004981 A MX2013004981 A MX 2013004981A MX 2013004981 A MX2013004981 A MX 2013004981A MX 2013004981 A MX2013004981 A MX 2013004981A MX 2013004981 A MX2013004981 A MX 2013004981A
Authority
MX
Mexico
Prior art keywords
therapeutics
delivery
methods
compositions
subject
Prior art date
Application number
MX2013004981A
Other languages
English (en)
Spanish (es)
Inventor
Alexander V Kabanov
Howard E Gendelman
Xin-Ming Liu
Original Assignee
Univ Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska filed Critical Univ Nebraska
Publication of MX2013004981A publication Critical patent/MX2013004981A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2013004981A 2010-11-02 2011-11-02 Composiciones y metodos para la administracion de agentes terapeuticos. MX2013004981A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40937210P 2010-11-02 2010-11-02
US201161526976P 2011-08-24 2011-08-24
PCT/US2011/058929 WO2012061480A2 (en) 2010-11-02 2011-11-02 Compositions and methods for the delivery of therapeutics

Publications (1)

Publication Number Publication Date
MX2013004981A true MX2013004981A (es) 2013-11-04

Family

ID=46025083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004981A MX2013004981A (es) 2010-11-02 2011-11-02 Composiciones y metodos para la administracion de agentes terapeuticos.

Country Status (8)

Country Link
US (1) US20130236553A1 (enExample)
EP (1) EP2635260A4 (enExample)
JP (1) JP2013542945A (enExample)
AU (1) AU2011323458B2 (enExample)
CA (1) CA2816123A1 (enExample)
MX (1) MX2013004981A (enExample)
RU (1) RU2632445C2 (enExample)
WO (1) WO2012061480A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
ITRM20120350A1 (it) * 2012-07-19 2014-01-20 Univ Degli Studi Milano Nanocostrutti con attività farmacologica.
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
WO2014169207A1 (en) * 2013-04-11 2014-10-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2015127437A1 (en) * 2014-02-24 2015-08-27 The Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
CN107708670A (zh) * 2015-06-01 2018-02-16 奥托泰利克有限责任公司 磷脂包衣的治疗剂纳米颗粒和有关的方法
EP3190176A1 (en) 2016-01-11 2017-07-12 IMBA-Institut für Molekulare Biotechnologie GmbH Method for tissue culture development on scaffold and differentiated tissue culture
US9872859B2 (en) * 2016-02-20 2018-01-23 The Florida International University Board Of Trustees Materials and methods for targeting therapeutic compositions to gut-associated lymphoid tissue (GALT)
JP7160466B2 (ja) 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL PRODRUGS AND THEIR FORMULATIONS
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
EP4751717A3 (en) 2018-10-22 2026-08-05 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
US9044381B2 (en) * 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
KR20060135729A (ko) * 2004-01-29 2006-12-29 백스터 인터내셔널 인코포레이티드 중추신경계 전달 증가를 위한 항레트로바이러스제의나노현탁액
RU2404988C2 (ru) * 2006-04-24 2010-11-27 Нм Тек Лтд. Наноматериалз Энд Микродевайсиз Текнолоджи Функциональные наноматериалы с антибактериальной и антивирусной активностью
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
WO2010009075A1 (en) * 2008-07-14 2010-01-21 The University Of North Carolina At Chapel Hill Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds

Also Published As

Publication number Publication date
EP2635260A4 (en) 2014-07-09
WO2012061480A3 (en) 2013-01-03
RU2632445C2 (ru) 2017-10-04
AU2011323458B2 (en) 2017-02-23
WO2012061480A2 (en) 2012-05-10
RU2013122656A (ru) 2014-12-10
JP2013542945A (ja) 2013-11-28
AU2011323458A1 (en) 2013-05-23
CA2816123A1 (en) 2012-05-10
EP2635260A2 (en) 2013-09-11
US20130236553A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
WO2012061480A3 (en) Compositions and methods for the delivery of therapeutics
JOP20180102A1 (ar) مركب صيدلاني
AU333422S (en) Showerhead
IN2014CN02639A (enExample)
GB201003973D0 (en) Fuel compositions
IN2015DN00127A (enExample)
SG195086A1 (en) Compounds containing hydrido-tricyano-borate anions
ZA201402988B (en) Dermal Delivery Compositions and Methods
MY173521A (en) Trpv4 antagonists
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX347771B (es) Polipeptidos antibacterianos quimericos.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
IN2014DN03298A (enExample)
MY161601A (en) Films and compositions comprising the same
IN2012DN03404A (enExample)
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
PH12013501192A1 (en) Pharmaceutical compositions
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
MX2013005759A (es) Metodos para detectar bajo grado de inflamacion.
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.
PH12014500432A1 (en) Stable compositions and methods for preparing the same
PH12012501547A1 (en) Methods of preparing thiazolidines
UA96060C2 (ru) Применение липофлавона как средства фригопротекторного действия
UA94339C2 (ru) применение корвитина в качестве средства фригопротекторного действия
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия